Casdin Capital as of Dec. 31, 2019
Portfolio Holdings for Casdin Capital
Casdin Capital holds 32 positions in its portfolio as reported in the December 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Sarepta Therapeutics (SRPT) | 8.0 | $87M | 670k | 129.04 | |
| Bluebird Bio (BLUE) | 7.8 | $85M | 970k | 87.75 | |
| Codexis (CDXS) | 7.5 | $81M | 5.1M | 15.99 | |
| Blueprint Medicines (BPMC) | 6.9 | $75M | 940k | 80.11 | |
| Myokardia | 6.7 | $73M | 1.0M | 72.88 | |
| Alnylam Pharmaceuticals (ALNY) | 5.5 | $59M | 515k | 115.17 | |
| Invitae (NVTAQ) | 5.4 | $59M | 3.6M | 16.13 | |
| Constellation Pharmceticls I | 5.2 | $57M | 1.2M | 47.11 | |
| Audentes Therapeutics | 4.7 | $52M | 860k | 59.84 | |
| Fate Therapeutics (FATE) | 4.6 | $50M | 2.6M | 19.57 | |
| Magenta Therapeutics | 4.3 | $47M | 3.1M | 15.16 | |
| Biolife Solutions (BLFS) | 3.7 | $40M | 2.5M | 16.18 | |
| Agios Pharmaceuticals (AGIO) | 3.6 | $39M | 825k | 47.75 | |
| Caredx (CDNA) | 2.4 | $26M | 1.2M | 21.57 | |
| Global Blood Therapeutics In | 2.2 | $24M | 300k | 79.49 | |
| Denali Therapeutics (DNLI) | 2.0 | $22M | 1.3M | 17.42 | |
| Fulcrum Therapeutics (FULC) | 1.9 | $21M | 1.2M | 16.64 | |
| Illumina (ILMN) | 1.8 | $20M | 60k | 331.73 | |
| Gritstone Oncology Ord (GRTS) | 1.8 | $19M | 2.2M | 8.97 | |
| Alector (ALEC) | 1.7 | $19M | 1.1M | 17.23 | |
| Sage Therapeutics (SAGE) | 1.5 | $17M | 230k | 72.19 | |
| GenMark Diagnostics | 1.5 | $16M | 3.4M | 4.81 | |
| Deciphera Pharmaceuticals (DCPH) | 1.5 | $16M | 255k | 62.24 | |
| Voyager Therapeutics (VYGR) | 1.4 | $15M | 1.1M | 13.95 | |
| Adaptive Biotechnologies Cor (ADPT) | 1.3 | $14M | 463k | 29.92 | |
| Gilead Sciences (GILD) | 1.2 | $13M | 200k | 64.98 | |
| Sangamo Biosciences (SGMO) | 1.1 | $12M | 1.5M | 8.37 | |
| Orchard Therapeutics Plc ads | 1.0 | $11M | 820k | 13.75 | |
| Twist Bioscience Corp (TWST) | 0.6 | $6.3M | 300k | 21.00 | |
| Turning Point Therapeutics I | 0.4 | $4.7M | 75k | 62.29 | |
| Rts/bristol-myers Squibb Compa | 0.4 | $4.5M | 1.5M | 3.01 | |
| Stoke Therapeutics (STOK) | 0.3 | $3.7M | 130k | 28.32 |
